Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Tiny balloon inside womb could help babies breathe

NCT ID NCT04052828

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tested a procedure called FETO, where a tiny balloon is placed in the windpipe of an unborn baby with severe congenital diaphragmatic hernia (CDH). The goal was to see if the balloon could be safely placed and removed to help the lungs grow. Four pregnant women participated, and the balloon was inserted between 27 and 29 weeks of pregnancy and removed around 34 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Goldballoon Detachable Balloon (GOLDBAL2) with Delivery Microcatheter
What this could lead to
If successful, this procedure could improve lung growth in fetuses with severe CDH, potentially increasing survival after birth.
What could go wrong
This is a very small pilot trial with only 4 participants, so results may not apply widely. The procedure carries risks like preterm labor or balloon complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

4 people

The number who actually took part.

Started

Apr 2021

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Signed and dated consent * Stated willingness to comply with all study procedures and availability for the duration of the study * Singleton pregnancy * No pathogenic variants on microarray or pathologic findings on karyotype * Fetal echocardiogram with changes expected with CDH and no major structural cardiac defects * Fetal CDH (left or right) with severe pulmonary hypoplasia, defined as observed-to-expected (o/e) lung to head ratios (LHR) \<25% with liver up * Gestational age at FETO procedure: if o/e LHR \<25% will be done at 27 weeks plus 0 days to 29 weeks plus 6 days * Meets psychosocial criteria * Willing to reside within 30 minutes of Von Voigtlander Women's Hospital and ability to maintain follow up appointments * Patient has a support person (e.g. spouse, partner, friend, parent) that is available to stay with her for the duration of the pregnancy near Von Voigtlander Women's Hospital * Willing to comply with restrictions of daily living including inability to exercise, have intercourse, or return to work. Exclusion Criteria: * Multi-fetal pregnancy * History of latex allergy * History of preterm labor or incompetent cervix (requiring cerclage), short cervix (≤20mm), or uterine anomaly predisposing to preterm labor * Bilateral CDH, unilateral CDH with o/e LHR \> 25%, or unilateral CDH with o/e LHR \<25% but liver completely down in abdomen * Additional fetal or genetic abnormalities that would impact care after delivery or be known to have an impact on outcome * Maternal contraindications to elective fetoscopic surgery * Significant placental abnormalities (abruption, chorioangioma, accreta) known at time of enrollment and/or surgery * Maternal isoimmunization or neonatal alloimmune thrombocytopenia * Maternal HIV, Hepatitis B with positive surface antigen, Hepatitis C with presence of virus in maternal blood due to risk of fetal transmission during the procedure * No safe or feasible fetoscopic approach to balloon placement * Social work will meet with each patient to evaluate the social situation and support system. Identifiable issues of social instability or compliance with the protocol will exclude her as a potential candidate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Congenital diaphragmatic hernia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.